研報掘金丨國金證券:維持萬華化學“買入”評級,24年主要產品銷量持續增長
國金證券研報指出,萬華化學(600309.SH)24年歸母淨利潤130.33億元,同比-22.49%。其中4季度歸母淨利潤19.4億,扣非後歸母淨利潤24.31億元。維持“買入”評級。2024年公司主要產品銷量持續增長,但受市場價格和原料成本波動因素影響,整體毛利同比基本持平;公司科研投入持續增加,銷售、管理、財務等三項費用同比增長;同時對部分投資項目計提資產減值準備或報廢處理,2024年歸屬於上市公司股東的淨利潤比上年同期下降22.49%。公司積極應對全球經濟貿易不確定性影響,不斷深化全球渠道佈局,通過數智化資源投入,持續提升裝置自主運行水平,多套裝置完成技改擴能。4季度MDI價格有所上升,價差有一定擴大;4季度家居和汽車行業需求同比下滑,軟泡聚醚4季度市場均價在8725元/噸左右。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.